1. Home
  2. PANW vs VRTX Comparison

PANW vs VRTX Comparison

Compare PANW & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Palo Alto Networks Inc.

PANW

Palo Alto Networks Inc.

HOLD

Current Price

$176.64

Market Cap

126.9B

Sector

Technology

ML Signal

HOLD

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$470.80

Market Cap

115.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
PANW
VRTX
Founded
2005
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Computer peripheral equipment
EDP Services
Sector
Technology
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
126.9B
115.7B
IPO Year
2012
1991

Fundamental Metrics

Financial Performance
Metric
PANW
VRTX
Price
$176.64
$470.80
Analyst Decision
Buy
Buy
Analyst Count
38
27
Target Price
$229.20
$512.63
AVG Volume (30 Days)
6.2M
1.5M
Earning Date
02-13-2026
02-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.58
14.22
Revenue
$9,556,500,000.00
$11,723,300,000.00
Revenue This Year
$16.49
$10.92
Revenue Next Year
$13.21
$8.56
P/E Ratio
$111.52
$33.45
Revenue Growth
15.30
10.33
52 Week Low
$144.15
$362.50
52 Week High
$223.61
$519.68

Technical Indicators

Market Signals
Indicator
PANW
VRTX
Relative Strength Index (RSI) 36.49 55.75
Support Level $171.25 $469.50
Resistance Level $189.39 $484.35
Average True Range (ATR) 5.32 11.79
MACD -0.69 1.26
Stochastic Oscillator 24.37 72.39

Price Performance

Historical Comparison
PANW
VRTX

About PANW Palo Alto Networks Inc.

Palo Alto Networks is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, and security operations. The California-based firm has more than 80,000 enterprise customers across the world, including more than three fourths of the Global 2000.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: